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Purpose/Objective: Patient 1: Prostate cancer diagnosis at the age of 
71 years in March 2004, T4N0M0, Gleason 4+5, PSA 14. MRI confirmed 
involvement of vesicles, rectum and bladder. Local EBRT with photons 
in daily 2 Gy fractions to 70 Gy and 6 months of neo-adjuvant GNRH 
analogue was supplied. Follow-up for 3 years, PSA <0.4 mg/l. In April 
2007 the patient had difficulties in interpretation of reading. CT, MRI, 
whole-body acetate-PET, methionin-PET and biopsy showed a solitary 
3.5 cm metastasis in the left temporal lobe as the only sign of disease 
recurrence. Rapid complete clinical response on steroids was declared 
by the patient. Local proton boost of 12 daily fractions of 2.4 Gy (RBE 
1.1), followed by photon EBRT to the whole brain of 15 daily fractions 
of 2 Gy, in total 61.1 Gy EDQ2 (a/b 3 Gy) was given to the metastatic 
lesion. Restart with GNRH analogue for 2 years followed by 
bicalutamide so far. During the follow-up for another 5 years repeated 
PET assessments reveal a very slow resolution of the lesion. The 
patient is still healthy without any signs of prostate cancer, only 
complaining about less memory capacity.  
Patient 2. Prostate cancer diagnosis at the age of 53 years in May 
2005, T4N0M0, Gleason 4+4, PSA 158 mg/l. MRI plus spectroscopy and 
acetate-PET confirmed involvement of the left vesicle. GNRH 
analogue and bicalutamide was supplied for 6 months before 
radiotherapy (RT) and then adjuvant for 5 years. The RT applied was 
local perineal proton boost involving a major part of the vesicles of 4 
daily fractions of 5 Gy followed by IMRT to prostate and pelvic nodes 
of 25 daily fractions of 2 Gy, with dose painting up to 2.2 Gy to a 
volume of persistent SUV uptake within prostate assessment just 
before start of RT. In total 87 Gy, EDQ2 (RBE 1.1, a/b 3 Gy) to the 
prostate and 94 Gy EDQ2 to the intraprostatic boost volume was 
supplied.  
During the follow-up of more than 7 years repeated acetate-PET 
assessments reveal a notably slow decline in SUV uptake. The patient 
is still healthy without any signs of prostate cancer or GU and GI 
toxicity.  
Materials and Methods: See above. 
Results: See above. 
Conclusions: Utilizing the best available imaging in staging of very 
high risk prostate cancer allows selection of patients for highly 
advanced delivery of radiotherapy and improvement of the prognosis. 
The slow decline in SUV reveals persistent metabolic activity, which 
suggests that the radiotherapy response is permanent growth arrest 
rather than mitotic cell kill.  
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Purpose/Objective: To compare the efficacy of external beam 
radiation therapy, I-125 brachytherapy, and HIFU destruction for 
localized Stage 1-2 prostate carcinoma. 
Materials and Methods: The patients with Stage 1 and 2 prostate 
carcinoma receiving local treatments in Samara Regional Oncological 
Center from October 2007 to January 2012 were chosen for analysis. 
The treatments were local (95% isodose to CTV) external beam 3D-
conformal or intensity-modulated radiation therapy to total 74-76 Gy 
(EBRT), LDR brachytherapy with permanent seeds I-125 to total dose 
140-145 Gy (BTI125), or HIFU ablation. Prior to HIFU all patients 
underwent transurethral resection of prostate. The primary endpoint 
was time to biochemical relapse, secondary endpoint – clinical 
progression free survival. The distribution by initial parameters was 
assessed using chi-square method. The survival comparison was made 
using Kaplan-Meier’s curves and log-rank method. Cox regression was 
applied to evaluate risk factors. 
Results: Of 181 selected patients, 66 received EBRT, 61 - BTI125, 
while remaining 54 patients were treated with HIFU. Median follow-
up, initial age, prostate volume, proportion of stage 1 and PSA level 
were 24, 56, 41 months; 71, 68, 69 years, 37, 32, 36 ml; 43%, 20%, 
28% (p=0.017) and 10, 12, 12 ng/ml for EBRT, BTI125, and HIFU 
groups, respectively. Biochemical progression occurred to 25 (46%) 
patients after HIFU therapy, while in the EBRT group – to 11 (18%) and 
in BTI125 – to 16 (24%). Median time to biochemical relapse were 61.0 
(95%confidence interval (CI), 55.0-67.3), 67.3 and 34.7 months, 
p<0.0001 for EBRT, BTI125, and HIFU, respectively. In Cox 
proportional hazards model after adjustment for stage, Gleason score 
and initial PSA, EBRT (OR 0.20, CI 95%, 0.09-0.42, p<0.0001) and 
BTI125 (OR 0.31, 95% CI, 0.13-0.74, p<0.0001) remained superior to 
HIFU by means of biochemical failure. 
 
  
Conclusions: Both external beam and interstitial radiation therapy 
explicit better efficacy as compared to HIFU therapy in the treatment 
of localized Stage 1-2 prostate carcinoma. 
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Purpose/Objective: The accurate delineation of both clinical target 
volumes (CTVs) and organs at risk (OARs) is crucial in modern prostate 
radiotherapy. However, this process is time consuming and subjected 
to considerable inter-clinician variation. Auto-contouring software 
could be one way of reducing outlining times and/or reducing inter-
clinician variation. MIM is a commercially available atlas-based auto-
contouring software package and the aims of this study are to 
determine whether MIM can reduce intra-clinician variability and 
delineation times for prostate cancer. 
Materials and Methods: Five cases of locally advanced prostate 
cancer were randomly selected and seven clinicians were asked to 
delineate CTVs and OARs using a set of delineation guidelines. Total 
time required for delineation was recorded using a stop watch. A MIM 
atlas of 50 patients was prepared and stratified according to bladder 
volumes. The MIM software (version 5.1) was then used to auto-
contour the 5 original cases and clinicians were asked to edit the 
auto-contoured structures and record delineation/correction times. 
The intra-clinician variation was assessed using conformity level (CL). 
The CL and delineation times were compared with and without MIM 
using a paired t-test. 
Results: The CL pre-MIM of CTV1 varied from 0.40-0.60 (mean 0.52) 
and CTV2 between 0.50-0.61 (mean 0.52). There was no significant 
improvement in CL using MIM software for CTV1 (mean 0.54, p=0.44) 
and CTV2 (mean 0.56, p=0.22). Mean bladder CL improved from 0.68 
to 0.74 (p=0.04) with no improvement for other OARs. The delineation 
times were not significantly shorter using MIM software except the 
right hip (table 1), but varied between clinicians (figure 1).  
 
Table 1: 
Structure Delineation time pre 
MIM (mean) 
Delineation time 
post MIM (mean) 
p value (using paired t 
test) and 95% CI 
CTV1 5 min 13 sec 4 min 26 sec 0.207 (-39.73-133.59) 
CTV2 1 min 48 sec 3 min 22 sec 0.0786 (-258.71-24.76) 
Bladder 2 min 32 sec 2 min 28 sec 0.800 (-0.110 to -0.006) 
Rectum 2 min 58 sec 3 min 22 sec 0.424 (-0.082 to 0.042) 
Right hip 1 min 42 sec 1 min 04 sec 0.005 (26.7-96.1) 
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Conclusions: Use of MIM software failed to improve the conformity 
level and showed no significant time-saving in this study. Further 
research and demonstrable benefits are required before it can be 
incorporated into routine practice for prostate cancer outlining. 
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Purpose/Objective: Accurate and reproducible patient (pts) 
positioning during radiotherapy is necessary for precise dose delivery. 
The aim of the study was to evaluate target positioning accuracy 
during prostate cancer (PC) treatment using cone beam CT (CBCT) 
image-guided localization system (XVI, Elekta) during a few fractions 
(fr) of radiotherapy. 
Materials and Methods: 22 pts with PC were treated in supine position 
on linear accelerator (Elekta Synergy) equipped with XVI (v.4.2). CBCT 
was performed according to our protocol on 1,2,3,4,11, 21 and 29 day 
of treatment. The results of matching the reference planning CT scans 
with CBCT datasets were represented as translations and rotations in 
3 directions: lateral (X), longitudinal (Y) and vertical (Z). However, 
the table on accelerator allowed correcting translations only. 
Results: The translations variations (cm) for the first three fractions 
were: on 1st fr:-0.06±0.25; 0.19±0.44; -0.11±0.33 in X,Y,Z direction, 
respectively. On the 2nd fr: -0.01±0.27; 0.16±0.47; -0.23±0.33 and on 
the 3rd fr: -0.09±0.34;0.14±0.38; -0.19±0.32 along X, Y and Z 
directions, respectively. The 3D vector was 0.53±0.36; 0.59±0.34; 
0.60±0.24 for the 1,2,3 fr respectively. On the 4 fr, after the 
calculation the mean of translations from the 1,2,3 fr, the X,Y,Zshifts 
were as follows: 0.9±0.29; 0.01±0.3; -0.09±0.24 with the vector length 
of 0.44±0.2. During the succeeding fr the following shifts in X, Y, Z 
direction were evaluated: on the 11th fr 0.05±0.33; 0.00±0.3; 
0.04±0.27; on the 21st fr-0.02±0.29; 0.09±0.37; -0.03±0.17 and on the 
29th fr -0.13±0.41; 0.07±0.29;0.10±0.27. The magnitude of 3D vector 
was 0.45±0.23; 0.45±0.22; 0.50±0.21 for the 11,21,29 fr, respectively. 
Conclusions: Our protocol seems to be a useful tool for overloaded 
radiotherapy departments, where performing every day CT-based 
IGRT is impossible. The greatest discrepancy between target position 
on reference planning CT and pretreatment CBCT on the accelerator 
was observed during the first fractions and decreased in the 
succeeding fr. The CBCT is a useful tool in determining and improving 
the accuracy of radiotherapy in PC. 
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Purpose/Objective: New technologies such as intensity modulated 
and image guided radiation therapy have been shown to decrease 
acute toxicity for prostate cancer (PC). We present the clinical results 
and the assessment of prognostic factors of radiation therapy with 
helical tomotherapy (HT) for clinically localized and recurrent PC, as 
well as post-prostatectomy adjuvant treatment. 
Materials and Methods: From May 2006 to January 2011, 70 cT1-T3 
cN0 cM0 PC patients were treated with HT (primary diagnosis, n=48; 
post-prostatectomy biochemical recurrence, n=15; post-brachytherapy 
biochemical recurrence, n=2; and post-prostatectomy adjuvance, 
n=5). The dose prescribed to the prostate ranged between 72-78Gy, 
except for one case (post-brachytherapy recurrence, 66Gy) with 
conventional fractionation (2Gy/fraction). The seminal vesicles 
received between 50-56Gy, the surgical bed 66-74Gy, and the pelvic 
lymph nodes 46-50.4Gy (n=20), respectively when applicable, with 
conventional fractionation. Genitourinary (GU) and gastrointestinal 
(GI) toxicity was scored using the Radiation Therapy Oncology Group 
(RTOG) scoring system. Potential risk factors for toxicity were 
assessed in univariate and multivariate logistic regression analysis. 
Results: The median age was 68 years (range 51-87 years). The 
median follow-up was 37 months (range 3-74 months). The mean 
initial Gleason score was 6 and the mean initial PSA was 17 ng/ml. For 
patients with a primary diagnosis or those receiving adjuvant HT, 
median overall survival was 45 months (range, 8-82 months). For 
patients receiving HT for biochemical recurrence, overall survival was 
24 months (range, 3-73 months). Overall, only 3 patients died, and 
none of them due to a cancer-related cause. Local recurrence was 
seen in 1 patient which had been treated for a biochemical recurrence 
after initial prostatectomy. Regional recurrence and bone disease only 
occurred in one patient with primary intermediate risk PC. The rates 
of acute grade 2 gastrointestinal (GI) and genitourinary (GU) toxicities 
were 13% and 10 %, respectively. Only one patient experienced acute 
grade 3 GU toxicity. The rates of late grade 2 GI toxicities were 1.5%, 
and those of late grade 2 GU toxicities were 1.2 %. No patients 
experienced late Grade ≥3 toxicity. Multivariate analysis showed that 
receiving a rectum mean dose >median (39 Gy) or a bladder median 
dose >median (46 Gy) was associated with a higher grade of acute GI 
(OR: 3.53; P =0.017) and GU toxicity, respectively (OR: 5.31; P 
=0.019). In addition, having an older age was associated with a higher 
grade of late GU toxicity (OR: 3.94; P =0.026). 
Conclusions: This preliminary report confirms the feasibility of HT for 
prostate cancer. HT is associated with a very low risk of toxicity and a 
low recurrence rate. Acute and late gastrointestinal and genitourinary 
toxicities were tolerable without any grade > 3 side effects.  
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Purpose/Objective: The aim of the present study was to evaluate the 
prevalence and severity of lower limb lymphedema after pelvic 
lymphadenectomy and radiotherapy to the pelvic lymph nodes in 
patients with prostate cancer. 
Materials and Methods: Twenty-six patients underwent combined 
treatment for high-risk node positive prostate cancer at the 
department of oncology at Skåne University Hospital between April 
2008 and March 2011. The treatment consisted of pelvic 
lymphadenectomy followed by androgen deprivation therapy and 
radiotherapy to the pelvic lymph nodes and prostate. The pelvic 
nodes, prostate and seminal vesicles were treated with external beam 
radiotherapy (EBRT) to an absorbed dose of 50 Gy followed by a 
brachytherapy boost of 2*10 Gy to the prostate only. Twenty-two 
patients accepted an invitation to a clinical examination with focus on 
lower limb swelling. The time between RT and examination was 
median 2.4 years (range 1.2-4.1 y). 
Results: Six patients (27%) experienced grade 1 lymphedema and two 
patients (9%) grade 2 while none had grade 3 or 4 according to the 
CTC Common Toxicity Criteria scale 4.0. Three patients required 
treatment with compression socks. 
Conclusions: Brachytherapy and pelvic EBRT have a low incidence of 
lymphedema in patients with high risk node positive prostate cancer 
that have undergone pelvic lymph node dissection. The follow-up time 






   
